Search

Search Constraints

You searched for: Author/Creator Natoli, Clara

Search Results

1. A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. (3rd July 2019)

2. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Issue 2 (1st February 2019)

3. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. Issue 1 (27th February 2019)

4. A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer. Issue 6 (30th November 2016)

5. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. (August 2020)

6. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. (2nd June 2016)

7. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. (March 2020)

8. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. Issue 5 (20th November 2015)

9. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Issue 4 (3rd April 2018)

10. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. Issue 1 (December 2017)